ProCE Banner Activity

CME

Ten Biomarkers Oncologists Need to Know for Personalized Cancer Care in 2018

Multimedia
Watch this CME/CE-certified Webcast of a dynamic CCO symposium at ASCO 2018 to review the ten most clinically relevant biomarkers in oncology with program chair John L. Marshall, MD, and experts Todd M. Bauer, MD; Hagop M. Kantarjian, MD; Edward S. Kim, MD, FACP; and Andrew D. Zelenetz, MD, PhD.

Physicians : maximum of 2.00 AMA PRA Category 1 {Credits}

Released: July 10, 2018

Expiration: July 09, 2019

No longer available for credit.

Share

Faculty

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Hagop M. Kantarjian

Hagop M. Kantarjian, MD

Chairman, Department of Leukemia
Professor of Medicine
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Edward S. Kim

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Andrew D. Zelenetz

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Agios Pharmaceuticals

Bayer Healthcare Pharma

Celgene TEXT Only

Foundation Medicine

Loxo Oncology

Merck Oncology

Target Audience

This program is intended for physicians, registered nurses, and other healthcare providers who care for patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply predictive biomarkers to guide therapeutic decisions in patients with cancer
  • Evaluate the available data and expert recommendations to determine which biomarkers should be tested in your patients with cancer
  • Explain to patients the need for an additional biopsy to test for appropriate biomarkers in cases where the initial biopsy sample was insufficient or if the biomarker status was previously unknown
  • Identify patients and determine eligibility to enroll on important ongoing clinical trials based on molecular testing of their tumor

Program Director Disclosure

Program Director

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees and fees for non-CME/CE services received directly from a commercial interest of their agents (eg, speaker bureaus) from Amgen, Bayer, Caris, Celgene, Genentech, and Taiho.

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD, has disclosed that he has received consulting fees from Guardant Health, Loxo Oncology, Ignyta, and Moderna Therapeutics.

Hagop M. Kantarjian, MD

Chairman, Department of Leukemia
Professor of Medicine
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Hagop M. Kantarjian, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, ARIAD Pharmaceuticals, Bristol-Myers Squibb, Immunogen, Orsinex, and Pfizer.

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Edward S. Kim, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Lilly, and Merck.

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Andrew D. Zelenetz, MD, PhD, has disclosed that he has received consulting fees from Adaptive Biotechnologies, Amgen, Celgene, Genentech/Roche, Gilead Sciences, Janssen, and Novartis and funds for research support from Gilead Sciences, MEI Pharma, and Roche.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 10, 2018, through July 09, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in applying biomarkers to guide cancer therapy.